The estimated Net Worth of Steven A Kriegsman is at least $2.14 Million dollars as of 7 August 2020. Mr. Kriegsman owns over 3,000,000 units of LadRx Corp stock worth over $434,900 and over the last 19 years he sold CYTR stock worth over $0. In addition, he makes $1,707,700 as Chairman of the Board and Chief Executive Officer at LadRx Corp.
Sign up
Mr. Kriegsman CYTR stock SEC Form 4 insiders trading
Steven has made over 2 trades of the LadRx Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 3,000,000 units of CYTR stock worth $780,000 on 7 August 2020.
The largest trade he's ever made was exercising 3,000,000 units of LadRx Corp stock on 7 August 2020 worth over $780,000. On average, Steven trades about 157,934 units every 154 days since 2005. As of 7 August 2020 he still owns at least 4,832,217 units of LadRx Corp stock.
You can see the complete history of Mr. Kriegsman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Kriegsman biography
Steven A. Kriegsman is Chairman of the Board, Chief Executive Officer of CytRx Corporation. He has been CytRx’s Chairman and Chief Executive Officer since October 2014. Prior to that, he served as CytRx’s President and Chief Executive Officer and a director since July 2002. He also serves as a director of Galena Biopharma, a listed public company, and is a member of its Compensation and its Strategy Committees. Mr. Kriegsman also serves on the Board of Directors of Catasys, Inc. He previously served as Director and Chairman of Global Genomics from June 2000 until 2002. Mr. Kriegsman is an inactive Chairman and Founder of Kriegsman Capital Group LLC, a financial advisory firm specializing in the development of alternative sources of equity capital for emerging growth companies in the healthcare industry. During his career, he has advised such companies as SuperGen Inc., Closure Medical Corporation, Novoste Corporation, Miravant Medical Technologies, and Maxim Pharmaceuticals. In the past five years, Mr. Kriegsman has also served on the board of directors of Bradley Pharmaceuticals, Inc. and Hythiam, Inc. Mr. Kriegsman has a B.S. degree with honors from New York University in Accounting and completed the Executive Program in Mergers and Acquisitions at New York University, The Management Institute. Mr. Kriegsman is a graduate of the Stanford Law School Directors’ College
What is the salary of Steven Kriegsman?
As the Chairman of the Board and Chief Executive Officer of LadRx Corp, the total compensation of Steven Kriegsman at LadRx Corp is $1,707,700. There are no executives at LadRx Corp getting paid more.
How old is Steven Kriegsman?
Steven Kriegsman is 78, he's been the Chairman of the Board and Chief Executive Officer of LadRx Corp since 2018. There are 2 older and 6 younger executives at LadRx Corp. The oldest executive at LadRx Corp is Louis Ignarro, 79, who is the Independent Director.
What's Steven Kriegsman's mailing address?
Steven's mailing address filed with the SEC is 11726 SAN VICENTE BLVD., SUITE 650, , LOS ANGELES,, CA, 90049.
Insiders trading at LadRx Corp
Over the last 21 years, insiders at LadRx Corp have traded over $0 worth of LadRx Corp stock and bought 3,710,406 units worth $8,711,088 . The most active insiders traders include Steven A Kriegsman, Scott Bradford Patterson, and Max Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of $22,531. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth $39,000.
What does LadRx Corp's logo look like?
Complete history of Mr. Kriegsman stock trades at LadRx Corp
LadRx Corp executives and stock owners
LadRx Corp executives and other stock owners filed with the SEC include:
-
Steven Kriegsman,
Chairman of the Board, Chief Executive Officer -
Steven A. Kriegsman,
Chief Exec. Officer -
John Caloz,
Chief Financial Officer, Chief Accounting Officer, IR Contact Officer -
John Y. Caloz,
CFO, Treasurer & Sr. VP -
Louis Ignarro,
Independent Director -
Joel Caldwell,
Director -
Earl Brien,
Director -
Dr. Felix Kratz Ph.D.,
Sr. VP, Drug Devel. -
Cristina Newman,
Corp. Sec. -
Terri Stevens,
Chief Bus. Officer -
Molly Painter,
Pres of USA and Head of Launch & Commercial Operations -
Molly Carey Poarch,
Global & U.S. Head of Corp. Communications -
Jennifer K. Simpson,
Director -
Anita J Chawla,
Director -
Daniel J Levitt,
Chief Medical Officer -
Joseph Rubinfeld,
Director -
Olivia C Ware,
Chief Commercial Officer -
Douglas Scott Wieland,
Sr. VP - Drug Development -
Felix Kratz,
Vice President Drug Discovery -
Herbert H Jr Mcdade,
-
Alexander L Cappello,
Director -
Raymond C Jr Carnahan,
-
Ben Levin,
Gen.Cnsl/VP Legal Affairs/Secy -
Eric Jay Selter,
Director -
Cheryl Cohen,
Director -
Scott Bradford Patterson,
10% owner -
Marvin R Selter,
Director -
Richard J Wennekamp,
Director -
Max Link,
Director -
David Scott Geyer,
Sr. V.P. of Manufacturing -
Mitchell K Fogelman,
Chief Financial Officer -
Jack R Barber,
Sr VP - Drug Development -
Shi Chung Ng,
Sr. VP Research & Development -
Matt Natalizio,
Chief Financial Officer -
Mark Tepper,
Vice President -
Stephen Snowdy,
Chief Executive Officer